The DIDO1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the DIDO1 gene in a heterogeneous HeLa cell background. This product provides a loss-of-function model for investigating the transcriptional co-regulator DIDO1, which plays pivotal roles in TGF-beta signaling, apoptosis regulation, and cell cycle control. The polyclonal format retains diverse editing events across the population, enabling robust functional studies without single-cell clonal selection. Researchers can employ these cells for rigorous pathway analysis, target validation, and mechanistic investigations in epithelial cancer biology.
HeLa cells, the host line for this knockout product, are derived from human cervical adenocarcinoma and represent a widely utilized immortalized cell model. These cells are positive for human papillomavirus 18 (HPV-18), resulting in functional inactivation of the tumor suppressors p53 and Rb by the viral oncoproteins E6 and E7. This genetic background renders HeLa cells particularly suitable for studying oncogenic signaling, DNA damage responses, and cell survival pathways. The combination of a well-characterized carcinoma model with targeted DIDO1 disruption provides a powerful platform for dissecting context-dependent gene functions.
The DIDO1 protein functions as a transcriptional co-regulator that integrates signals from the TGF-beta superfamily to modulate gene expression programs. It interacts with key mediators SMAD2 and SMAD3, and forms complexes with transcriptional coactivators EP300 and CREBBP, as well as the corepressor HDAC1, to fine-tune transcriptional responses. Downstream of TGF-beta receptor activation, DIDO1 influences the expression of pro-apoptotic genes such as BAX and cell cycle regulators like CDKN1A. Its activity is triggered by cellular stress signals and upstream TGF-beta ligands, placing DIDO1 at a critical node controlling apoptosis and proliferation.
In the HeLa carcinoma context, knockout of DIDO1 is anticipated to impair TGF-beta-mediated transcriptional responses and alter cell survival pathways. Because HeLa cells already harbor disrupted p53 and Rb pathways via HPV-18 E6/E7, the additional loss of DIDO1 may reveal synergistic effects on apoptosis susceptibility and cell cycle progression. This model enables detailed interrogation of how DIDO1 coordinates with SMAD2/3, EP300, and other factors to regulate gene expression in a cervical adenocarcinoma setting, offering insights into mechanisms of chemoresistance and oncogenic transformation.
Typical research applications include TGF-beta signaling pathway analysis, apoptosis mechanism studies, cancer cell biology, and drug target validation. The cells are compatible with a range of downstream assays, such as western blotting for protein expression changes, RT-qPCR for transcriptional targets, luciferase reporter assays for TGF-beta/SMAD activity, immunofluorescence to assess SMAD nuclear translocation, Annexin V/PI staining for apoptosis, flow cytometry for cell cycle distribution, and co-immunoprecipitation to examine DIDO1 interactions. For further details or technical support, please contact Ascent Research.
